NYSE:BHVN

Biohaven Pharmaceutical Stock Forecast, Price & News

$97.27

-0.45 (-0.46 %)

(As of 06/24/2021 12:00 AM ET)

Add

Compare

Today's Range

$97.10

▼

$99.40

50-Day Range

$66.05

▼

$105.02

52-Week Range

$57.66

▼

$106.57

Volume534,275 shs

Average Volume864,675 shs

Market Capitalization$6.33 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.01

30 days | 90 days | 365 days | Advanced Chart

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical: Return On Capital Employed Insights
June 23, 2021 | benzinga.com

Biohaven Appoints Kishen Mehta to Board of Directors
June 17, 2021 | finance.yahoo.com

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
June 15, 2021 | finance.yahoo.com

Biohaven Pharmaceutical (NYSE:BHVN) Trading Down 7.1%
June 15, 2021 | americanbankingnews.com

Biohaven Pharmaceutical (NYSE:BHVN) Hits New 1-Year High at $101.40
June 10, 2021 | americanbankingnews.com

Critical Contrast: Biohaven Pharmaceutical (NYSE:BHVN) vs. Artelo Biosciences (NASDAQ:ARTL)
June 10, 2021 | americanbankingnews.com

Biohaven Pharmaceuticals Looks Ready to Trade Higher
June 9, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?
June 9, 2021 | finance.yahoo.com

Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
June 8, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Insights: Return On Capital Employed
June 7, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:BHVN
Previous SymbolNASDAQ:BHVN
CUSIPN/A
CIK1689813
Webwww.biohavenpharma.com
Phone203-404-0410
Employees825
Year FoundedN/A

Sales & Book Value

Annual Sales$63.63 million
Price / Sales99.47
Cash FlowN/A
Price / Cash FlowN/A
Book Value($6.54) per share
Price / Book-14.87

Profitability

EPS (Most Recent Fiscal Year)($13.06)
Net Income$-766,800,000.00
Net Margins-804.24%
Return on EquityN/A
Return on Assets-113.79%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares65,070,000
Market Cap$6.33 billion
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.23 out of 5 stars

Medical Sector

936th out of 2,106 stocks

Pharmaceutical Preparations Industry

456th out of 832 stocks

1.5 Analyst's Opinion

Consensus Rating
Biohaven Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $103.89, Biohaven Pharmaceutical has a forecasted upside of 6.8% from its current price of $97.27.
Amount of Analyst Coverage
Biohaven Pharmaceutical has only been the subject of 4 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Biohaven Pharmaceutical has received 333 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biohaven Pharmaceutical has received 357 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biohaven Pharmaceutical has received 51.74% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote “Outperform” if you believe BHVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biohaven Pharmaceutical does not currently pay a dividend.
Dividend Growth
Biohaven Pharmaceutical does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biohaven Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.20% of the stock of Biohaven Pharmaceutical is held by insiders.
Percentage Held by Institutions
92.11% of the stock of Biohaven Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($13.47) to ($9.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biohaven Pharmaceutical is -6.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biohaven Pharmaceutical is -6.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical or view top-rated stocks.

What stocks does MarketBeat like better than Biohaven Pharmaceutical?

Wall Street analysts have given Biohaven Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biohaven Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced its quarterly earnings results on Sunday, May, 9th. The company reported ($4.21) EPS for the quarter, missing the Zacks' consensus estimate of ($2.92) by $1.29. The business earned $43.82 million during the quarter, compared to the consensus estimate of $36.46 million. Biohaven Pharmaceutical's revenue was up 3710.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.39) earnings per share.
View Biohaven Pharmaceutical's earnings history.

How has Biohaven Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BHVN stock has increased by 146.5% and is now trading at $97.27.
View which stocks have been most impacted by COVID-19.

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical updated its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $43.80 million-$43.80 million, compared to the consensus revenue estimate of $36.41 million.

What price target have analysts set for BHVN?

10 analysts have issued 12-month price targets for Biohaven Pharmaceutical's shares. Their forecasts range from $69.00 to $140.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $103.89 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:

Dr. Vladimir Coric, CEO, Pres & Director (Age 50, Pay $1.26M)
Mr. James Engelhart, CFO & Treasurer (Age 57, Pay $717.04k)
Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 55, Pay $654.99k)
Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $726.79k)
Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 57, Pay $931.82k)
Mr. Matthew DeLawder, Director of Accounting
Dr. Charles Conway, Chief Scientific Officer (Age 59)
Ms. Wendy Goss, Exec. Admin. Assistant
Mr. Clifford Bechtold M.S., Pres & GM of Biohaven Ireland and Chief Compliance Officer
Ms. Jenny Strauss M.P.H., Mang. of Medical Information & Communication

Who are some of Biohaven Pharmaceutical's key competitors?

Some companies that are related to Biohaven Pharmaceutical include MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Catalent (CTLT), Viatris (VTRS), Elanco Animal Health (ELAN), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), CureVac (CVAC), Maravai LifeSciences (MRVI) and Ono Pharmaceutical (OPHLF).
View all of BHVN's competitors.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital International Investors (8.57%), BlackRock Inc. (6.10%), Stifel Financial Corp (3.94%), JPMorgan Chase & Co. (2.83%), Alliancebernstein L.P. (2.35%) and Bank of New York Mellon Corp (1.91%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical.

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Cormorant Asset Management LP, Nuveen Asset Management LLC, Morgan Stanley, Barclays PLC, Opaleye Management Inc., Panagora Asset Management Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Gregory Bailey, Kimberly Gentile, Robert Berman, and William A Jones Jr.
View insider buying and selling activity for Biohaven Pharmaceutical or view top insider-selling stocks.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenview Capital Management LLC, Armistice Capital LLC, Bank of New York Mellon Corp, Oak Ridge Investments LLC, BlackRock Inc., Alliancebernstein L.P., and Capital International Investors. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric.
View insider buying and selling activity for Biohaven Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $97.27.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $6.33 billion and generates $63.63 million in revenue each year. The company earns $-766,800,000.00 in net income (profit) each year or ($13.06) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 825 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.

This page was last updated on 6/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here